London, X0, based Investment company Abingworth LLP (Current Portfolio) buys NuCana PLC, Verona Pharma PLC, sells CRISPR Therapeutics AG, Protara Therapeutics Inc during the 3-months ended 2020Q3, according to the most recent filings of the investment company, Abingworth LLP. As of 2020Q3, Abingworth LLP owns 14 stocks with a total value of $252 million. These are the details of the buys and sells.
For the details of Abingworth LLP's stock buys and sells,
go to www.gurufocus.com/guru/abingworth+llp/current-portfolio/portfolio
These are the top 5 holdings of Abingworth LLP
- Personalis Inc (PSNL) - 4,462,452 shares, 38.31% of the total portfolio. Shares reduced by 18.11%
- Phathom Pharmaceuticals Inc (PHAT) - 1,203,135 shares, 17.63% of the total portfolio.
- Soleno Therapeutics Inc (SLNO) - 10,302,602 shares, 10.20% of the total portfolio.
- CRISPR Therapeutics AG (CRSP) - 259,599 shares, 8.59% of the total portfolio. Shares reduced by 50%
- NuCana PLC (NCNA) - 3,333,333 shares, 6.83% of the total portfolio. New Position
New Purchase: NuCana PLC (NCNA)
Abingworth LLP initiated holding in NuCana PLC. The purchase prices were between $4.57 and $6.48, with an estimated average price of $5.42. The stock is now traded at around $4.78. The impact to a portfolio due to this purchase was 6.83%. The holding were 3,333,333 shares as of .
Added: Verona Pharma PLC (VRNA)
Abingworth LLP added to a holding in Verona Pharma PLC by 172.47%. The purchase prices were between $4.45 and $10.2, with an estimated average price of $6.87. The stock is now traded at around $6.95. The impact to a portfolio due to this purchase was 3.84%. The holding were 2,457,499 shares as of .
Sold Out: Protara Therapeutics Inc (TARA)
Abingworth LLP sold out a holding in Protara Therapeutics Inc. The sale prices were between $16.76 and $31.89, with an estimated average price of $23.21.
Here is the complete portfolio of Abingworth LLP. Also check out: